Clinical trial
Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia
NCT00051298 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00051298 |
|---|---|
| Title | Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia |
| Official title | Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Olanzapine, Placebo |
| Enrollment | 107 |
| Start date | Nov 1, 2002 |
| Completion | Apr 1, 2005 |
| First posted | Jan 9, 2003 |
| Last update posted | Jun 12, 2007 |
| Countries | Russia, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: